MM-141
Product
Merrimack Pharmaceuticals, Inc.
Total Payments
$371,857
Transactions
88
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $371,857 | 88 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $371,857 | 88 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MM-141-07-02-02 | Merrimack Pharmaceuticals, Inc. | $305,628 | 0 |
| A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors | Merrimack Pharmaceuticals, Inc. | $66,229 | 0 |
Top Doctors Receiving Payments for MM-141
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Park Ridge, IL | $371,857 | 88 |
Ad
Manufacturing Companies
- Merrimack Pharmaceuticals, Inc. $371,857
Product Information
- Type Product
- Total Payments $371,857
- Total Doctors 0
- Transactions 88
About MM-141
MM-141 is a product associated with $371,857 in payments to 0 healthcare providers, recorded across 88 transactions in the CMS Open Payments database. The primary manufacturer is Merrimack Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $371,857 was paid across 88 transactions to 0 doctors.
The most common payment nature for MM-141 is "Unspecified" ($371,857, 100.0% of total).
MM-141 is associated with 2 research studies, including "MM-141-07-02-02" ($305,628).